The second abstract presents the discovery of a novel CNS-penetrating ATR inhibitor, also developed through AI, targeting the DNA damage repair pathway.

Rakovina's preclinical pipeline is dedicated to targeting DNA-repair vulnerabilities in solid tumors, particularly in challenging cancers such as breast, ovarian, prostate, and brain cancers.

The company's use of AI platforms, including Deep-Docking™ and Enki™, enhances the efficiency of drug discovery by allowing for rapid evaluation of potential drug compounds.

As of March 2025, Rakovina's stock has seen a year-to-date price decline of 27.78%, with an average trading volume of 279,735 shares and a current market capitalization of C$11.97 million.

Rakovina Therapeutics Inc. has announced that two of its research abstracts have been accepted for presentation at the prestigious 2025 American Association for Cancer Research (AACR) Annual Meeting.

The AACR Annual Meeting serves as a global platform for unveiling advancements in cancer research, attracting leading scientists and biotech innovators.

This recognition underscores Rakovina's advancements in AI-driven drug discovery, which is poised to transform cancer therapies.

One of the abstracts focuses on the development of novel PARP1-selective inhibitors for brain tumors, leveraging artificial intelligence to overcome challenges such as blood-brain barrier permeability and off-target effects associated with current PARP inhibitors.

The new AI-driven approach aims to create more effective treatments against brain tumors and metastases, addressing the limitations of existing ATR inhibitors.

The research utilized Deep Docking, a deep learning virtual screening method, to analyze billions of compounds and identify those with strong PARP1 selectivity and potential for effective brain penetration.

In vitro and in vivo testing confirmed the efficacy, selectivity, and pharmacokinetic properties of these AI-discovered compounds, marking a significant advancement in treatment options for brain tumors.